Imvax Inc.

About Imvax Inc.

Imvax is a biotechnology company focused on developing personalized, whole tumor-derived immunotherapies. Their mission is to turn the complexity of solid tumors against themselves by capturing a tumor's full antigen signature to stimulate patients' innate and adaptive immunity against remaining tumor cells.

Products & Services

Goldspire(r) Platform:A unique platform that captures a tumor's full antigen signature to stimulate immunity against tumor cells.

IGV-001:A lead program in clinical trials for newly diagnosed Glioblastoma.

IHC-001, IUC-001, ICC-001, IEC-001, IOC-001:Additional programs in Imvax's pipeline for various solid tumors.

Specialties

Personalized immunotherapies Whole tumor-derived treatments Glioblastoma treatment Solid tumor research

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Financing Round T: - FT: Financing Round	A: 29000000 MR: - FA: $29 million FAN: 29000000	D: 2025-01-29 FD: 2025-01-29	1 investors

Financing Round Latest

2025-01-29

$29.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

John P. Furey

Chief Executive Officer

D

David W. Andrews, M.D.

Co-Founder, Chief Medical Officer

M

Mark A. Exley, Ph.D.

Chief Scientific Officer

S

Sean P. Hemingway

Chief Operating Officer

J

John M. Limongelli

Chief Legal Officer

D

Diana Martine

Head of Human Resources

View 21 more team members with Pro

Unlock Full Team Directory

Recent News

Imvax Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised